作者
Günter U Höglinger, Irene Litvan, Nuno Mendonca, Deli Wang, Hui Zheng, Beatrice Rendenbach-Mueller, Hoi-Kei Lon, Ziyi Jin, Nahome Fisseha, Kumar Budur, Michael Gold, Davis Ryman, Hana Florian, Anwar Ahmed, Ikuko Aiba, Alberto Albanese, Kelly Bertram, Yvette Bordelon, James Bower, Jared Brosch, Daniel Claassen, Carlo Colosimo, Jean-Christophe Corvol, Paola Cudia, Antonio Daniele, Luc Defebvre, Erika Driver-Dunckley, Antoine Duquette, Roberto Eleopra, Alexandre Eusebio, Victor Fung, David Geldmacher, Lawrence Golbe, Francisco Grandas, Deborah Hall, Taku Hatano, Lawrence Honig, Jennifer Hui, Diana Kerwin, Akio Kikuchi, Thomas Kimber, Takashi Kimura, Rajeev Kumar, Peter Ljubenkov, Stefan Lorenzl, Albert Ludolph, Zoltan Mari, Nikolaus McFarland, Wassilios Meissner, Pablo Mir Rivera, Hidek Mochizuki, John Morgan, Renato Munhoz, Noriko Nishikawa, OSullivan John, Tomoko Oeda, Hideki Oizumi, Osamu Onodera, Fabienne Ory-Magne, Elizabeth Peckham, Ronald Postuma, Aldo Quattrone, Joseph Quinn, Stefano Ruggieri, Justyna Sarna, Paul E Schulz, John Slevin, Michele Tagliati, Daryl Wile, Zbigniew Wszolek, Tao Xie, Theresa Zesiewicz
发表日期
2021/3/1
期刊
The Lancet Neurology
卷号
20
期号
3
页码范围
182-192
出版商
Elsevier
简介
Background
Progressive supranuclear palsy is a neurodegenerative disorder associated with tau protein aggregation. Tilavonemab (ABBV-8E12) is a monoclonal antibody that binds to the N-terminus of human tau. We assessed the safety and efficacy of tilavonemab for the treatment of progressive supranuclear palsy.
Methods
We did a phase 2, multicentre, randomised, placebo-controlled, double-blind study at 66 hospitals and clinics in Australia, Canada, France, Germany, Italy, Japan, Spain, and the USA. Participants (aged ≥40 years) diagnosed with possible or probable progressive supranuclear palsy who were symptomatic for less than 5 years, had a reliable study partner, and were able to walk five steps with minimal assistance, were randomly assigned (1:1:1) by interactive response technology to tilavonemab 2000 mg, tilavonemab 4000 mg, or matching placebo administered intravenously on days 1, 15 …
学术搜索中的文章
GU Höglinger, I Litvan, N Mendonca, D Wang, H Zheng… - The Lancet Neurology, 2021